Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MLi-2 是一种结构新颖、高效、选择性的 LRRK2 激酶抑制剂,具有中枢神经系统活性,IC50为 0.76 nM,有潜力用于帕金森氏病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 529 | 现货 | ||
2 mg | ¥ 772 | 现货 | ||
5 mg | ¥ 1,180 | 现货 | ||
10 mg | ¥ 1,790 | 现货 | ||
25 mg | ¥ 2,970 | 现货 | ||
50 mg | ¥ 4,470 | 现货 | ||
100 mg | ¥ 6,370 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 987 | 现货 |
产品描述 | MLi-2 is a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity. MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM). |
靶点活性 | LRRK2:0.76 nM |
体外活性 |
MLi-2, a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity.?MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).?MLi-2 has greater than 295-fold selectivity for over 300 kinases in addition to a diverse panel of receptors and ion channels. |
体内活性 |
MLi-2, a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity.?MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).?MLi-2 has greater than 295-fold selectivity for over 300 kinases in addition to a diverse panel of receptors and ion channels. |
分子量 | 379.46 |
分子式 | C21H25N5O2 |
CAS No. | 1627091-47-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (158.12 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6353 mL | 13.1766 mL | 26.3532 mL | 65.8831 mL |
5 mM | 0.5271 mL | 2.6353 mL | 5.2706 mL | 13.1766 mL | |
10 mM | 0.2635 mL | 1.3177 mL | 2.6353 mL | 6.5883 mL | |
20 mM | 0.1318 mL | 0.6588 mL | 1.3177 mL | 3.2942 mL | |
50 mM | 0.0527 mL | 0.2635 mL | 0.5271 mL | 1.3177 mL | |
100 mM | 0.0264 mL | 0.1318 mL | 0.2635 mL | 0.6588 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MLi-2 1627091-47-7 Autophagy LRRK2 MLi2 Inhibitor Leucine-rich repeat kinase 2 inhibit disease orally Parkinson’s MLi 2 inhibitor